Human α-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice

Molecular Cancer Therapeutics

Volumn 7, Issue 6, 2008, Pages 1588-1597

  Xu, Ning ^a   Wang, Yong Sheng ^a   Pan, Wu Bin ^a   Xiao, Bo ^a   Wen, Yan Jun ^a   Chen, Xian Cheng ^b   Chen, Li Juan ^a   Deng, Hong Xin ^a   You, Jia ^a   Kan, Bing ^a   Fu, A Fu ^a   Li, Dan ^a   Zhao, Xia ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA DEFENSIN; ALPHA DEFENSIN 1; PLASMID VECTOR; UNCLASSIFIED DRUG; DEFENSIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; ANIMAL; CELL DEATH; CELL PROLIFERATION; CELL STRAIN COS1; CERCOPITHECUS; DRUG SCREENING; INTRACELLULAR SPACE; LUNG TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; WEIGHT GAIN;

ADENOCARCINOMA; ALPHA-DEFENSINS; ANIMALS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; INTRACELLULAR SPACE; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; WEIGHT GAIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 49849090945     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0010     Document Type: Article

References (35)

1. Ganz T, Lehrer RI. Defensins. Pharmacol Ther 1995;66:191-205.
2. Lichtenstein A. Mechanism of mammalian cell lysis mediated by peptide defensins. Evidence for an initial alteration of the plasma membrane. J Clin Invest 1991;88:93-100.
3. Lichtenstein A, Ganz T, Selsted ME, Lehrer RI. In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes. Blood 1986;68:1407-10.
4. Lichtenstein AK, Ganz T, Nguyen TM, Selsted ME, Lehrer RI. Mechanism of target cytolysis by peptide defensins. Target cell metabolic activities, possibly involving endocytosis, are crucial for expression of cytotoxicity. J Immunol 1988;140:2686-94.
5. Wimley WC, Selsted ME, White SH. Interactions between human defensins and lipid bilayers: evidence for formation of multimeric pores. Protein Sci 1994;3:1362-73.
6. Aarbiou J, Tjabringa GS, Verhoosel RM, et al. Mechanisms of cell death induced by the neutrophil antimicrobial peptides α-defensins and LL-37. Inflamm Res 2006;55:119-27.
7. Muller CA, Markovic-Lipkovski J, Klatt T, et al. Human α-defensins HNPs-1, -2, and -3 in renal cell carcinoma: influences on tumor cell proliferation. Am J Pathol 2002;160:1311-24.
8. Hubert P, Herman L, Maillard C, et al. Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre)neoplastic lesions formed in vitro and transplanted in vivo. FASEB J 2007;21:2765-75.
9. Economopoulou M, Bdeir K, Cines DB, et al. Inhibition of pathologic retinal neovascularization by α-defensins. Blood 2005;106:3831-8.
10. Chavakis T, Cines DB, Rhee JS, et al. Regulation of neovascularization by human neutrophil peptides (α-defensins): a link between inflammation and angiogenesis. FASEB J 2004;18:1306-8.
11. Folkman J. Angiogenesis. Annu Rev Med 2006;57:1-18.
12. Grutkoski PS, Graeber CT, Lim YP, Ayala A, Simms HH. α-Defensin 1 (human neutrophil protein 1) as an antichemotactic agent for human polymorphonuclear leukocytes. Antimicrob Agents Chemother 2003;47:2666-8.
13. Chaly YV, Paleolog EM, Kolesnikova TS, Tikhonov, II, Petratchenko EV, Voitenok NN. Neutrophil α-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells. Eur Cytokine Netw 2000;11:257-66.
14. Shi J, Zheng D, Liu Y, et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005;65:1687-92.
15. Lin X, Chen X, Wei Y, et al. Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice. Gynecol Oncol 2007;104:540-6.
16. Khazanov E, Simberg D, Barenholz Y. Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice. J Gene Med 2006;8:998-1007.
17. Van Wetering S, Mannesse-Lazeroms SP, Dijkman JH, Hiemstra PS. Effect of neutrophil serine proteinases and defensins on lung epithelial cells: modulation of cytotoxicity and IL-8 production. J Leukoc Biol 1997;62:217-26.
18. Okrent DG, Lichtenstein AK, Ganz T. Direct cytotoxicity of polymorphonuclear leukocyte granule proteins to human lung-derived cells and endothelial cells. Am Rev Respir Dis 1990;141:179-85.
19. Selsted ME, Ouellette AJ. Mammalian defensins in the antimicrobial immune response. Nat Immunol 2005;6:551-7.
20. Zapata JM, Pawlowski K, Haas E, Ware CF, Godzik A, Reed JC. A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J Biol Chem 2001;276:24242-52.
21. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
22. Halder TM, Bluggel M, Heinzel S, Pawelec G, Meyer HE, Kalbacher H. Defensins are dominant HLA-DR-associated self-peptides from CD34(-) peripheral blood mononuclear cells of different tumor patients (plasmacytoma, chronic myeloid leukemia). Blood 2000;95:2890-6.
23. Lehrer RI, Barton A, Daher KA, Harwig SS, Ganz T, Selsted ME. Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J Clin Invest 1989;84:553-61.
24. 1 with the central cell-binding domain of fibronectin. Am J Pathol 2000;156:1345-62.
25. 1 integrins. Proc Natl Acad Sci U S A 2003;100:4766-71.
26. Bdeir K, Cane W, Canziani G, et al. Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood 1999;94:2007-19.
27. Higazi AA, Ganz T, Kariko K, Cines DB. Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells. J Biol Chem 1996;271:17650-5.
28. Territo MC, Ganz T, Selsted ME, Lehrer R. Monocyte-chemotactic activity of defensins from human neutrophils. J Clin Invest 1989;84:2017-20.
29. Chertov O, Michiel DF, Xu L, et al. Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 1996;271:2935-40.
30. Yang D, Chen Q, Chertov O, Oppenheim JJ. Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J Leukoc Biol 2000;68:9-14.
31. Yang D, Chertov O, Bykovskaia SN, et al. β-Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999;286:525-8.
32. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005;55:178-94.
33. Avradopoulos K, Mehta S, Blackinton D, Wanebo HJ. Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck. Ann Surg Oncol 1997;4:184-90.
34. Feldman AL, Restifo NP, Alexander HR, et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 2000;60:1503-6.
35. Gorrin-Rivas MJ, Arii S, Furutani M, et al. Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin Cancer Res 2000;6:1647-54.